Grace Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.), a Delaware corporation, filed this Current Report on Form 8-K on November 13, 2024. The filing serves to announce the company's financial results for the fiscal quarter ended September 30, 2024. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol GRCE.
Financial Metrics
This Form 8-K acts as a notification of the release of financial results and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The detailed financial metrics are contained within the press release furnished as Exhibit 99.1, which is not included in the provided text. Therefore, the filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that a press release detailing the results for the quarter ended September 30, 2024, was issued on November 13, 2024.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Key Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1, as this 8-K does not list the numbers.
- Confirm the company's name change from Acasti Pharma Inc. to Grace Therapeutics, Inc.
- Note that the financial data referenced in this filing is not legally "filed" under Section 18 of the Exchange Act within this specific document.
- Check the company's liquidity status and cash runway in the full press release, as this 8-K provides no data on debt or cash flow.